Group 1 - The seventh supervisory board meeting of Sichuan Shengda Forestry Industry Co., Ltd. was held, with all three participating supervisors voting in favor of the resolutions [1][2] - The supervisory board approved the 2025 semi-annual report, confirming that the report accurately reflects the company's actual situation without any false records or misleading statements [1][2] - The supervisory board also approved the special report on the use of raised funds, agreeing with the board's assessment and committing to ensure compliance in the management of these funds [2] Group 2 - The meeting was conducted in accordance with the Company Law and the company's articles of association, ensuring proper governance [1] - The supervisory board will actively supervise the board and management to ensure effective measures are taken for the proper use of raised funds, protecting the interests of the company and all shareholders [2] - Relevant documents, including the semi-annual report and the special report on the use of raised funds, were disclosed on designated information platforms [1][2]

Group 1 - The company held its 10th meeting of the second Supervisory Board, which was conducted via communication, with all 5 supervisors present, ensuring compliance with relevant laws and regulations [1] - The Supervisory Board approved the 2025 semi-annual report and its summary, confirming that the report accurately reflects the company's actual situation and complies with legal requirements [1][2] - The board also approved the special report on the storage and actual use of raised funds for the first half of 2025, confirming compliance with regulations and no misuse of funds [2] Group 2 - The board agreed to cancel the Supervisory Board and transfer its powers to the Audit Committee of the Board, while also approving a capital increase of 4.90 shares for every 10 shares held, totaling 115,743,812 shares [2][3] - The proposal to change the registered capital and amend the company's articles of association will be submitted to the shareholders' meeting for approval [3]

Meeting Overview - The fourth meeting of the Supervisory Board of Suzhou Minxin Microelectronics Technology Co., Ltd. was held on August 28, 2025, in accordance with legal and regulatory requirements [1]. Financial Report Approval - The Supervisory Board approved the 2025 semi-annual report, confirming that its preparation and review complied with relevant laws and regulations, and accurately reflected the company's financial status and operational results for the first half of 2025 [2][3]. Fund Management - The management and actual use of raised funds for the first half of 2025 were found to be in compliance with regulatory guidelines, ensuring that funds were stored in dedicated accounts and used for specified purposes without any violations [2][3]. Auditor Appointment - The Supervisory Board agreed to appoint Zhihong Accounting Firm as the financial and internal control auditor for the year 2025, with the decision pending approval at the upcoming shareholders' meeting [3]. Asset Impairment Provision - The decision to recognize asset impairment provisions for the first half of 2025 was deemed appropriate and compliant with accounting standards, ensuring accurate financial reporting without harming the interests of shareholders [4].

Group 1 - The board of directors of Wuhan San Zhen Industrial Holdings Co., Ltd. held its 43rd meeting on August 28, 2025, with all 11 directors present, complying with the Company Law and the company's articles of association [1][2] - The meeting approved the 2025 semi-annual report and summary, which had been reviewed by the audit committee [1] - The company established a "Market Value Management Measures" in accordance with various regulatory guidelines to enhance market value management [2] - The company revised its "Fundraising Management Measures" to improve the efficiency of fundraising usage, aligning with new legal regulations effective from July 1, 2024, and March 28, 2025 [2]

Meeting Overview - The 21st meeting of the 4th Supervisory Board of Suzhou Ruikeda Connection System Co., Ltd. was held on August 28, 2025, with all three supervisors present [1][2]. Financial Report Approval - The Supervisory Board approved the 2025 semi-annual report, confirming that the report's preparation and review procedures comply with legal regulations and internal management systems, accurately reflecting the company's financial status and operational results [2][3]. Fund Management Report Approval - The Supervisory Board approved the special report on the management and actual use of raised funds for the first half of 2025, stating that the management of these funds complies with relevant regulations and that the disclosed information is accurate and complete [2][3]. Idle Fund Management Approval - The Supervisory Board approved the use of up to RMB 200 million of idle self-owned funds for cash management in safe and liquid investment products, ensuring that this will not affect the company's normal operations or the interests of shareholders, particularly minority shareholders [3].

Summary of Key Points Core Viewpoint - Beijing Shoulv Hotel Group Co., Ltd. has reported on the management and usage of raised funds for the first half of 2025, highlighting compliance with regulatory requirements and detailing the allocation of funds for hotel expansion and upgrades. Fundraising Overview - The company was approved to issue 134,348,410 shares at a price of RMB 22.33 per share, raising a total of RMB 2,994,275,995.30, with net proceeds of RMB 2,990,790,514.72 after deducting issuance costs [1][2] - As of June 30, 2025, the company has utilized RMB 1,619,257,322.74 for hotel expansion and upgrades, and RMB 900,000,000.00 for repaying bank loans, totaling RMB 2,519,257,322.74 in usage, leaving a balance of RMB 471,533,191.98 [1][2] Fund Management - The company has established a dedicated fund management system, ensuring that raised funds are stored and managed in specialized accounts [1][2] - As of June 30, 2025, the balance in the fundraising special account was RMB 44,641,805.17, including interest income [1][2] Investment Projects - The company has approved the use of RMB 153,479,401.99 to replace self-raised funds previously invested in hotel expansion and upgrades [2][3] - There were no instances of using idle funds to temporarily supplement working capital as of June 30, 2025 [2][3] Cash Management - The company has utilized idle funds for cash management, investing a total of RMB 8,550,000,000.00 in financial products, with RMB 8,000,000,000.00 redeemed upon maturity [3][6] - As of June 30, 2025, the company has not recovered the principal of RMB 55,000,000.00 from the financial products purchased with idle funds [3][6] Compliance and Reporting - The company has adhered to regulatory requirements and internal management protocols, ensuring accurate and timely disclosure of fundraising usage and management [2][3][6] - There have been no violations in the management and usage of raised funds as of June 30, 2025 [2][3][6]

Core Viewpoint - The company has announced the completion of several fundraising projects and plans to allocate the remaining funds to other ongoing projects, enhancing the efficiency of fund utilization and supporting the company's operational needs [1][2][11]. Fundraising and Project Overview - The total amount raised through a targeted issuance of A-shares was approximately RMB 573.18 million, with net proceeds after expenses amounting to RMB 572.37 million [2][3]. - The projects that have been completed include: - "Hucun Water Plant Project (Phase I)" - "Lanxi City Dengsheng Water Plant Project" - "Fuzhou Jiangyin Port City Economic Zone Sewage Treatment Plant Mid-term Project (Phase I)" - "Changshan Overseas Chinese Town Sewage Treatment Plant Expansion and Upgrade Project" [1][2][4]. Remaining Fund Allocation - The remaining funds amount to RMB 106.86 million, which will be redirected to the following projects: - "Yongkang City Sewage Treatment Plant (Phase V)" - "Pinghu City Dushan Port Industrial Water Plant Phase III" [1][5][9]. Fund Utilization Efficiency - The decision to reallocate the remaining funds is based on the actual construction status of the projects, aiming to avoid idle funds and improve the efficiency of fund usage, which is expected to enhance the company's economic benefits [4][11]. Approval Process - The board of directors has approved the reallocation of funds, and the sponsor, CITIC Securities, has provided a clear consent opinion, confirming that the necessary approval procedures have been followed [2][11].

Fundraising Overview - The company raised a total of RMB 581,020,898.64 through a specific stock issuance at a price of RMB 8.72 per share, with a net amount of RMB 572,370,632.48 after deducting issuance costs of RMB 8,650,266.16 [1][2] - The funds were fully deposited into the company's account by December 2, 2024, and verified by Tianjian Accounting Firm on December 3, 2024 [2] Fund Management - The company has established a special account for the management of the raised funds at China Merchants Bank, ensuring compliance with regulations and protecting investors' rights [3] - A tripartite supervision agreement was signed with the underwriter and the bank to regulate the storage of the raised funds [3] Fund Utilization - As of June 30, 2025, the total amount used from the raised funds was RMB 350,216,297.34, with RMB 110,000,000.00 allocated for cash management [2][4] - The company has generated interest income of RMB 720,621.05 and investment income from financial products of RMB 1,199,884.92, resulting in a remaining balance of RMB 114,074,841.11 in the special account [2][4] Project Investment and Replacement - The company approved the use of raised funds to replace self-raised funds previously invested in projects, totaling RMB 312,306,495.90 [5] - The company has completed the replacement of pre-invested funds for various projects, ensuring compliance with regulatory requirements [5][6] Cash Management - The company has been authorized to use up to RMB 300 million of temporarily idle raised funds for cash management, ensuring that this does not affect the normal use of the funds for project construction [5][7] - The company has engaged in structured deposits with China Merchants Bank, generating returns from these investments [7] Project Completion and Surplus Funds - Several projects have been completed and reached a usable state, resulting in surplus funds of RMB 10,685.60 million, which will be redirected to other ongoing projects [8] - The company has adhered to regulations regarding the use of raised funds, ensuring transparency and compliance in its disclosures [8]

Summary of Key Points Core Viewpoint - The company, Fujian Foxit Software Development Co., Ltd., has utilized its own funds to pay for investment projects and subsequently replaced these with equivalent amounts from raised funds, ensuring compliance with regulatory requirements and enhancing operational efficiency [1][6]. Group 1: Fundraising Overview - The company was approved to publicly issue 12.04 million shares at a price of RMB 238.53 per share, raising a total of RMB 2,871,901,200, with a net amount of RMB 2,586,478,593.67 after deducting issuance costs [1][2]. - As of June 30, 2025, the remaining balance of raised funds was RMB 437,639,800 [2]. Group 2: Investment Project Status - The total investment in various projects includes: - PDF Product R&D and Upgrade: RMB 179,070,900 (completed) - Document Intelligent Cloud Service: RMB 152,764,100 (completed) - Cutting-edge Document Technology R&D: RMB 13,835,700 (completed) - Property Purchase for Fuzhou R&D Center: RMB 42,220,000 (completed) - Permanent Supplement to Working Capital: RMB 1,306,000,000 (completed) - Global Marketing Service Network: RMB 557,800,900 (ongoing) - Intelligent Document Processing Platform: RMB 278,014,700 (ongoing) - Share Buyback: RMB 15,774,300 (completed) - Acquisition of Foxit Kunpeng Equity: RMB 90,238,100 (ongoing) [2]. Group 3: Reasons and Process for Fund Replacement - The company opted to use its own funds for initial payments due to operational efficiency and compliance with banking regulations regarding salary payments, which require the use of basic or general accounts [3][4]. - The process involves the finance manager's review, board approval, and subsequent transfer of equivalent amounts from the raised funds account to the company's basic account [5]. Group 4: Impact on Daily Operations - The use of self-funds for project payments is expected to enhance operational management efficiency and ensure the smooth progress of investment projects without affecting the normal implementation of these projects [5][6]. Group 5: Review Procedures - The board and supervisory committee approved the use of self-funds for project payments and the subsequent replacement with raised funds, confirming compliance with relevant regulations [6][7].

Summary of Key Points Core Viewpoint The report outlines the fundraising activities and the utilization of funds by Shanghai Haoyuan Pharmaceutical Co., Ltd. for the first half of 2025, detailing the amount raised, the allocation of funds, and the management of these funds. Group 1: Fundraising Overview - The company raised a total of RMB 822.35 million through the issuance of convertible bonds, with a maturity of 6 years and a face value of RMB 100 per bond [1][2]. - As of June 30, 2025, the balance in the fundraising account was RMB 420,589,058.15, which includes interest income after deducting fees [1][2]. Group 2: Fund Utilization - The net amount of funds raised was RMB 811,737,609.85, with RMB 311,050,738.57 allocated to investment projects and RMB 86 million used for cash management [1][2]. - The company has not used any idle funds for temporary working capital during the reporting period [2][3]. Group 3: Fund Management - The company established a dedicated account for the management of raised funds, ensuring compliance with regulations and maintaining transparency [1][2]. - A three-party supervision agreement was signed with banks and the sponsor to oversee the management of the funds [1][2]. Group 4: Project Updates - The company has approved the use of raised funds to replace pre-invested self-raised funds amounting to RMB 40,333,017.97 for specific projects [2][3]. - The timeline for certain projects has been extended, with the "High-end Pharmaceutical Intermediates and Raw Materials CDMO Industrialization Project" expected to reach operational status by June 2029 [3][4]. Group 5: Compliance and Reporting - The company has adhered to the regulatory requirements for fundraising and has accurately disclosed the status of fund utilization [3][4]. - No violations in the management of raised funds have been reported, and all disclosures have been made in a timely and accurate manner [3][4].